
LIXTE Biotechnology's LB-100 Compound Aims to Enhance Standard Cancer Treatments
LIXTE Biotechnology is developing LB-100, a novel PP2A inhibitor designed to make cancer cells more responsive to existing immunotherapies and chemotherapies, potentially addressing treatment resistance and limited efficacy in oncology.
Read full story

























